IF 1.5 4区医学

Xenobiotica Pub Date : 2026-10-20 DOI: 10.1080/00498254.2026.2747092

Tsukasa Kobayashi, Yuko Takeba, Kouichi Sugaya, Masanori Ootaki, Yuki Ohta, Taroh Iiri, Naoki Matsumoto, Jun-Ichi Onose, Naoki Abe, Keisuke Kida

{"title":"Metabolic profile of thiopental and cytochrome P450-mediated drug interactions in rats.","authors":"Tsukasa Kobayashi, Yuko Takeba, Kouichi Sugaya, Masanori Ootaki, Yuki Ohta, Taroh Iiri, Naoki Matsumoto, Jun-Ichi Onose, Naoki Abe, Keisuke Kida","doi":"10.1080/00498254.2026.2747092","DOIUrl":"10.1080/00498254.2026.2747092","url":null,"abstract":"1. Pentobarbital is metabolised by cytochrome P450 (CYP) enzymes, being a model compound for evaluating CYP-mediated drug-drug interactions, has become difficult to obtain for animal studies in Japan. The metabolic pathway of thiopental (TP), a barbiturate with similar pharmacological properties, remains insufficiently characterised. This study investigated TP metabolic profile, with emphasis on CYP modulator-induced drug-drug interactions.2. TP was administered intraperitoneally to either phenobarbital (PB), chloramphenicol (CP)-pre-treated, or untreated rats. Plasma TP concentrations were quantified using HPLC-DAD and a plate reader. Hypnotic and sedative properties were assessed by time to loss of righting reflex and recovery from hindlimb paralysis. TP metabolism was further evaluated in vitro using rat liver microsomes (RLMs) and recombinant CYP enzymes, and hepatic CYP mRNA levels were quantified by real-time RT-PCR.3. Compared with TP alone, PB pre-treatment shortened TP-induced anaesthesia and decreased plasma TP concentrations, whereas CP pre-treatment prolonged the duration of action and increased plasma TP levels. TP metabolism was mediated by CYP2B1 and CYP2C11. PB pre-treatment induced CYP2B1 and enhanced TP metabolism, whereas CP pre-treatment suppressed CYP2C11, inhibited CYP2B1, and reduced TP metabolism.4. These results suggest that TP is a useful alternative model compound for investigating pharmacokinetics/pharmacodynamics and CYP-mediated drug-drug interactions.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"1-9"},"PeriodicalIF":1.5,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149149297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetics of metoprolol in cisgender males, cisgender females, and transgender women receiving gender-affirming hormone therapy: an exploratory pilot study. 美托洛尔在接受性别确认激素治疗的顺性男性、顺性女性和变性女性中的药代动力学：一项探索性试点研究。

IF 1.5 4区医学

Xenobiotica Pub Date : 2026-10-19 DOI: 10.1080/00498254.2026.2751094

Badriyah Shadid Alotaibi, Sadia Khalid, Abdul Muqeet Khan, Manal A Buabeid, Ghulam Murtaza

{"title":"Pharmacokinetics of metoprolol in cisgender males, cisgender females, and transgender women receiving gender-affirming hormone therapy: an exploratory pilot study.","authors":"Badriyah Shadid Alotaibi, Sadia Khalid, Abdul Muqeet Khan, Manal A Buabeid, Ghulam Murtaza","doi":"10.1080/00498254.2026.2751094","DOIUrl":"10.1080/00498254.2026.2751094","url":null,"abstract":"1. To characterise metoprolol pharmacokinetics and assess the feasibility of pharmacokinetic sampling among cisgender males, cisgender females, and transgender women receiving gender-affirming hormone therapy.2. Nine healthy volunteers (three per group) received a single 100 mg oral dose of metoprolol, and serial blood samples were collected over 12 h. Plasma metoprolol concentrations were determined using HPLC and analysed by a non-compartment model. CYP2D6 genotyping or phenotyping was not performed; therefore, the analysis was descriptive and hypothesis-generating.3. Descriptively, mean area under the concentration-time curve values were 2550 ± 126 ng·h/mL in cisgender males, 2142 ± 463 ng·h/mL in cisgender females, and 1522 ± 189 ng·h/mL in transgender participants. Mean peak plasma concentrations were 418 ± 43, 363 ± 58, and 269 ± 27 ng/mL, respectively. The corresponding elimination rates were 0.139, 0.140, and 0.268 h-1, and mean half-lives were 4.98, 4.92, and 2.58 h, respectively.4. The observed profiles suggest between-participant variability that warrants further investigation; however, three participants per group cannot represent the respective populations, and the findings cannot be attributed to sex, gender, or hormone therapy without CYP2D6 genotype data. Larger, genotype-stratified studies with detailed hormone and body-composition measurements are required.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"1-5"},"PeriodicalIF":1.5,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Absorption, distribution, metabolism, and excretion of linzagolix after a single oral dose in rats and monkeys. 大鼠和猴子单次口服林扎哥利克斯的吸收、分布、代谢和排泄。

IF 1.5 4区医学

Xenobiotica Pub Date : 2026-10-19 DOI: 10.1080/00498254.2026.2752069

Yasuyuki Toyoda, Hiroshi Harada, Takuro Endo, Yoshikazu Abe, Kaoru Kobayashi

{"title":"Absorption, distribution, metabolism, and excretion of linzagolix after a single oral dose in rats and monkeys.","authors":"Yasuyuki Toyoda, Hiroshi Harada, Takuro Endo, Yoshikazu Abe, Kaoru Kobayashi","doi":"10.1080/00498254.2026.2752069","DOIUrl":"https://doi.org/10.1080/00498254.2026.2752069","url":null,"abstract":"1. Linzagolix is an orally available gonadotropin-releasing hormone antagonist used to treat female-specific diseases, such as uterine fibroids and endometriosis.2. After a single dose of [14C]linzagolix or linzagolix to female rats and monkeys, linzagolix exhibited the absorption-distribution-metabolism-excretion characteristics of acidic drugs owing to the presence of a carboxylic acid moiety in its structure.3. Linzagolix showed low total clearance, high oral bioavailability, and high plasma exposure associated with high solubility, low metabolic clearance, and entero-hepatic circulation. Linzagolix had a low-volume distribution with limited tissue distribution associated with high plasma protein binding. These absorption-distribution-metabolism-excretion characteristics were comparable between the two species.4. After a single oral dose of [14C]linzagolix to rats, radioactivity was rapidly distributed to almost all tissues; however, the extent of the tissue distribution was limited and decreased in parallel with elimination from the blood.5. In both species, linzagolix was identified as the primary circulating and excretory component. The major biotransformation pathways of linzagolix were two O-demethylations and O-debenzylation. Additionally, sulphate conjugates of O-demethylated metabolites were detected in rats.6. The major excretion route of linzagolix was faecal excretion via the bile in its unchanged form.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"1-35"},"PeriodicalIF":1.5,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gut microbiota-mediated biotransformation of coumarins. 肠道菌群介导的香豆素生物转化。

IF 1.5 4区医学

Xenobiotica Pub Date : 2026-10-19 DOI: 10.1080/00498254.2026.2747088

Jennifer Carolina Flores Iglesias, Luis Fernando Méndez López

{"title":"Gut microbiota-mediated biotransformation of coumarins.","authors":"Jennifer Carolina Flores Iglesias, Luis Fernando Méndez López","doi":"10.1080/00498254.2026.2747088","DOIUrl":"10.1080/00498254.2026.2747088","url":null,"abstract":"Coumarins are plant-derived secondary metabolites widely present in foods, spices, and medicinal plants. Their limited intestinal absorption and extensive host metabolism allow a variable fraction to reach the colon, where gut microorganisms can transform them into metabolites with distinct physicochemical and biological properties.This review synthesizes current evidence on gut microbiota-mediated coumarin biotransformation, focusing on microbial taxa, metabolic reactions, structural determinants, and consequences for biological activity. Reported transformations include deglycosylation, reduction, O-demethylation, hydroxylation, deprenylation, and lactone ring opening. Recent studies have identified multiple human gut bacteria capable of coumarin reduction and implicated the NADPH-dependent reductase NemA in this process. Gut bacteria may also generate simple coumarins from dietary phenolic precursors. These transformations can modify biological activity, while coumarins and their metabolites may reciprocally influence microbial composition and metabolism.Current evidence supports gut microbiota as an important determinant of coumarin metabolism, but its physiological relevance in humans remains uncertain. Key gaps include interindividual variability, specific microbial enzymes and taxa, enterohepatic recycling, and the contribution of the gut mycobiome. Integrated microbiome, metabolomic, and pharmacokinetic approaches are needed to establish the contribution of microbiota-derived metabolites to coumarin bioactivity and safety.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"1-16"},"PeriodicalIF":1.5,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Landscape of small molecules derived from marine sources and their clinical progression. 海洋小分子来源的景观及其临床进展。

IF 1.5 4区医学

Xenobiotica Pub Date : 2026-10-19 DOI: 10.1080/00498254.2026.2751092

Murugesan Vanangamudi, Aditya Vikram Jain, Thakur Gurjeet Singh, Kapil Kumar Goel, Nisha Bansal

{"title":"Landscape of small molecules derived from marine sources and their clinical progression.","authors":"Murugesan Vanangamudi, Aditya Vikram Jain, Thakur Gurjeet Singh, Kapil Kumar Goel, Nisha Bansal","doi":"10.1080/00498254.2026.2751092","DOIUrl":"10.1080/00498254.2026.2751092","url":null,"abstract":" Marine organisms have fascinated scientists with their unique and unparalleled biodiversity and therapeutic potential.They are known to possess novel bioactive compounds with varied pharmacological properties that encompass anticancer, antimicrobial, anti-inflammatory, neuroprotective, antiviral, and cardioprotective properties.The review is put forth to discuss key advancements in landscapes of small molecules derived from marine sources, along with their clinical status.We also identify key challenges in marine drug discovery, such as access to marine organisms, supply chain sustainability, chemical diversity, synthesis complexity, bioavailability optimisation, and intellectual property concerns.The review also put forth the discussions on improving the drug discovery area from marine sources by considering the advancements in marine biotechnology, artificial intelligence, and interdisciplinary collaborations.Redressing these challenges and adopting emerging technologies, the potential of marine biodiversity may be harnessed for biomedical innovation and, in turn, contribute to health and promote environmental sustainability.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"1-18"},"PeriodicalIF":1.5,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antifungal ototoxicity, itraconazole, and approaches to its mitigation: a review of a sparse evidence base. 抗真菌耳毒性，伊曲康唑及其缓解方法：对稀疏证据基础的回顾。

IF 1.5 4区医学

Xenobiotica Pub Date : 2026-10-19 DOI: 10.1080/00498254.2026.2752067

Martin Vališ, Kateřina Juklová, Radka Skorunková, Štěpán Frydrych, Simona Halúsková

{"title":"Antifungal ototoxicity, itraconazole, and approaches to its mitigation: a review of a sparse evidence base.","authors":"Martin Vališ, Kateřina Juklová, Radka Skorunková, Štěpán Frydrych, Simona Halúsková","doi":"10.1080/00498254.2026.2752067","DOIUrl":"https://doi.org/10.1080/00498254.2026.2752067","url":null,"abstract":"1. introduction: Hearing loss is a recognised hazard of aminoglycosides and platinum chemotherapy, but the auditory risk of antifungal drugs has received far less attention. Itraconazole lists hearing loss in its prescribing information, yet dedicated peer-reviewed auditory studies appear absent.2. areas covered: The original 139-record Web of Science (WoS) title-only corpus was retained to map the wider ototoxicity field. A targeted WoS Topic-field sensitivity search using antifungal-specific terms and broader auditory outcomes retrieved 153 records, of which 18 direct antifungal auditory safety/toxicity studies were retained. No dedicated auditory study of itraconazole was identified. The expanded evidence shows formulation- and route-dependent topical effects, a pharmacovigilance signal for oral terbinafine, no auditory brainstem response shift in a short-duration animal study of systemic voriconazole or caspofungin, and rare hearing-loss reports plus a pharmacovigilance signal for amphotericin B. Otoprotection evidence from other drug classes is considered for transferable mitigation principles.3. expert opinion: The broader search shows a heterogeneous but sparse evidence base rather than an absence of evidence. Human systemic azole data remain particularly limited, and itraconazole lacks dedicated auditory investigation. Baseline and serial audiometry, separation of drug effects from infection and interacting medicines, and mechanistic studies are priorities.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"1-23"},"PeriodicalIF":1.5,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoparticle-based oral delivery of capecitabine: in vitro cytotoxicity and pharmacokinetic evaluation in HepG2 and HT-29 cell lines. 纳米粒口服卡培他滨：HepG2和HT-29细胞系的体外细胞毒性和药代动力学评价

IF 1.5 4区医学

Xenobiotica Pub Date : 2026-10-18 DOI: 10.1080/00498254.2026.2745909

Shraddha K Vedpathak, Chitra C Khanwelkar, Anuradha N Chivate, Niranjan D Chivate

{"title":"Nanoparticle-based oral delivery of capecitabine: in vitro cytotoxicity and pharmacokinetic evaluation in HepG2 and HT-29 cell lines.","authors":"Shraddha K Vedpathak, Chitra C Khanwelkar, Anuradha N Chivate, Niranjan D Chivate","doi":"10.1080/00498254.2026.2745909","DOIUrl":"10.1080/00498254.2026.2745909","url":null,"abstract":"Present study aims to develop and assess a capecitabine-loaded nanoparticle formulation (C18) for improved oral bioavailability and targeted anticancer activity.Capecitabine nanoparticles were successfully prepared using a double emulsion solvent evaporation process. These nanoparticles were then tested for in vitro cytotoxicity using MTT assays against HT-29, HepG2 and L929 cell lines to calculate IC50 values. The pharmacokinetic properties of the medication and its nanoparticle formulation were also investigated in Wistar rats after oral administration. Validated HPLC methods were used to assess the plasma concentrations of 5-FU and capecitabine, and data was processed using PkSolver software.The nanoparticle formulation (C18) exhibited dose-dependent cytotoxicity by IC50 values of 38.91 µg/mL (HepG2) and 55.15 µg/mL (HT-29), showing superior anticancer activity compared to 5-FU. Cytotoxicity towards normal L929 cells was moderate, indicating selective toxicity. Pharmacokinetic studies revealed enhanced oral bioavailability, increased Cmax and AUC, and prolonged circulation time for the nanoparticle formulation compared to the conventional drug.Capecitabine-loaded nanoparticles demonstrated improved cytotoxic potential against cancer cell lines and favourable pharmacokinetic profiles, associate their probability as an active oral nanocarrier system for cancer therapy.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"1-8"},"PeriodicalIF":1.5,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early-Life Minocycline Exposure Produces Sustained Redox Modulation but Persistent Locomotor Deficits in Drosophila melanogaster. 早期二甲胺四环素暴露在黑腹果蝇中产生持续的氧化还原调节但持续的运动缺陷。

IF 1.5 4区医学

Xenobiotica Pub Date : 2026-10-15 DOI: 10.1080/00498254.2026.2751095

Oluwasegun Davis Olatomide, Chika Timileyin Emmanuel, Tolulope Timothy Arogundade, Tomiwa Goodness Alake, Oyindamola Deborah Idowu, Ugonna Tolulope Akin-Adekeye, Olayinka Tawose, Olamilekan Francis Ajayi, Babatunde Mobolaji Oguntimehin, Queenesther Ikheme Adeyinka, Dayo Rotimi Omotoso

{"title":"Early-Life Minocycline Exposure Produces Sustained Redox Modulation but Persistent Locomotor Deficits in Drosophila melanogaster.","authors":"Oluwasegun Davis Olatomide, Chika Timileyin Emmanuel, Tolulope Timothy Arogundade, Tomiwa Goodness Alake, Oyindamola Deborah Idowu, Ugonna Tolulope Akin-Adekeye, Olayinka Tawose, Olamilekan Francis Ajayi, Babatunde Mobolaji Oguntimehin, Queenesther Ikheme Adeyinka, Dayo Rotimi Omotoso","doi":"10.1080/00498254.2026.2751095","DOIUrl":"https://doi.org/10.1080/00498254.2026.2751095","url":null,"abstract":"1. Minocycline has shown therapeutic potential in neurodegeneration and ageing, but the effects of exposure during development remain poorly understood. This study investigated whether minocycline exposure restricted to development alters redox status and locomotor function in adult Drosophila melanogaster after drug withdrawal.2. A preliminary adult survival assay was used to inform dose selection. Fly eggs were cultured on standard food containing minocycline at 0.05, 0.10 or 0.20 mM from embryonic development through eclosion. Adults were then transferred to untreated food and assessed on post-eclosion day 5. Larval feeding and body-wall contraction were assessed as developmental behavioural endpoints, adult climbing performance was assessed using the negative geotaxis assay, and redox status was evaluated using FOX-reactive peroxides, nitric oxide-related measures, thiols and malondialdehyde.3. Developmental minocycline exposure reduced FOX-reactive peroxide and nitric oxide-related measures and increased thiol levels in adults. Exposure also impaired larval feeding and adult climbing performance, whereas pupation and larval crawling were not significantly altered.4. Developmental minocycline exposure was associated with altered redox status and locomotor deficits that remained evident in early adulthood following drug withdrawal. These findings support further investigation of the tissue-specific and molecular mechanisms underlying the effects of developmental minocycline exposure.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"1-17"},"PeriodicalIF":1.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Male reproductive tissues express cytochrome P450 isoforms involved in the in situ metabolism of the pesticide methyl parathion in the mouse. 雄性生殖组织表达参与农药甲基对硫磷原位代谢的细胞色素P450异构体。

IF 1.5 4区医学

Xenobiotica Pub Date : 2026-10-11 DOI: 10.1080/00498254.2026.2717191

Patricia Espíritu-Gordillo, Yuliana Palacios-Gil, María de Jesús Solís-Heredia, Ma de Lourdes López-González, Adolfo Sierra-Santoyo, Betzabet Quintanilla-Vega

{"title":"Male reproductive tissues express cytochrome P450 isoforms involved in the in situ metabolism of the pesticide methyl parathion in the mouse.","authors":"Patricia Espíritu-Gordillo, Yuliana Palacios-Gil, María de Jesús Solís-Heredia, Ma de Lourdes López-González, Adolfo Sierra-Santoyo, Betzabet Quintanilla-Vega","doi":"10.1080/00498254.2026.2717191","DOIUrl":"10.1080/00498254.2026.2717191","url":null,"abstract":"This study aimed to evaluate the bioactivation of methyl-parathion (Me-Pa) and the expression and activity of mouse cytochrome P450 (Cyp) isoforms involved, in the cauda epididymis-vas deferens (CE-VD) and testis, and in the liver for comparison.Microsomes were obtained from adult mice treated and non-treated with phenobarbital (PB), and the bioactivation of Me-Pa was indirectly evaluated by in vitro acetylcholinesterase inhibition. The protein content was evaluated by immunoblotting, and the enzymatic activities by resorufin ether-O-dealkylation and 16α- and 6β-testosterone hydroxylation. Me-Pa bioactivation was observed in the testis at a lower rate than in the liver and was detected in the CE-VD only after PB induction.The protein content and enzymatic activities associated with the Cyps evaluated were observed in all tissues in different proportions, depending on the enzyme. In all cases, protein content and enzymatic activities in the liver were higher than in reproductive tissues, except for Cyp1a2, for which constitutive expression was not observed in the CE-VD, but its associated enzymatic activity was higher compared to the testis and liver.These findings suggest that mouse reproductive tissues are metabolically active in biotransforming xenobiotics, such as Me-Pa, contributing to its toxicity.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"1-10"},"PeriodicalIF":1.5,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Jujuboside A inhibits the progression of ischemic stroke by regulating miR-583. 红枣苷A通过调节miR-583抑制缺血性脑卒中的进展。

IF 1.5 4区医学

Xenobiotica Pub Date : 2026-10-08 DOI: 10.1080/00498254.2026.2737214

Tengfei Yuan, Zhenxiong Guo

{"title":"Jujuboside A inhibits the progression of ischemic stroke by regulating miR-583.","authors":"Tengfei Yuan, Zhenxiong Guo","doi":"10.1080/00498254.2026.2737214","DOIUrl":"https://doi.org/10.1080/00498254.2026.2737214","url":null,"abstract":"Objective: Jujuboside A (JuA) possesses anti-inflammatory and antioxidant activities; however, its role and mechanisms of action in ischemic stroke (IS) remain unclear.Methods: A mouse MCAO was established to evaluate the effects of different doses of JuA on brain water content, neurological function scores, behavioral parameters, inflammatory factors, and oxidative stress markers. An OGD model was established in SH-SY5Y cells. Cell viability and apoptosis were assessed by the CCK-8 assay and flow cytometry. Inflammatory factors were evaluated via ELISA, and oxidative stress markers were assessed by commercial kits. RT-qPCR was used to analyze changes in miR-583 expression under OGD conditions.Results: JuA dose-dependently alleviated cerebral edema, neurological deficits, and motor dysfunction in MCAO mice; it reduced TNF-α, IL-6, IL-1β, MDA, and LDH, and increased SOD levels. Under OGD conditions, JuA (40 μM) significantly improved SH-SY5Y cell viability and reduced cell apoptosis, inflammatory responses, and oxidative stress. Furthermore, inhibition of miR-583 abolished the protective effects of JuA.Conclusion: By upregulating miR-583 to suppress inflammation and oxidative stress, JuA alleviates IS injury and represents a promising candidate neuroprotective compound.","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"1-15"},"PeriodicalIF":1.5,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Xenobiotica最新文献